Pfizer

Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer

PfizerPreliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advanced breast cancer. These data were presented this week at the 14th European Cancer Conference (ECCO 14) in Barcelona.

Gastric cancer is the fourth most common form of cancer worldwide. The development of gastric cancer has been linked to chronic infection with H. pylori, one of the most common bacterial infections worldwide with a particularly high prevalence in developing countries.

"Gastric cancer remains a leading cause of cancer death in many parts of the world and, as the cancer is often diagnosed at an advanced stage, the development of additional effective treatment options is essential," said Yung-Jue Bang, MD, professor of Internal Medicine of the Seoul National University College of Medicine. "Though preliminary, these results are promising and support additional study of sunitinib malate in advanced gastric cancer, which typically has a poor prognosis with five-year survival around 25%."

Phase II Study in Advanced Gastric Cancer
Preliminary findings from this phase II, open-label, multicenter study indicate that single-agent sunitinib malate showed anti-tumor activity with manageable adverse events in previously chemotherapy-treated patients with advanced gastric cancer. Patients in the trial received sunitinib malate 50mg/day, administered in six-week cycles of four weeks on treatment followed by two weeks off. The trial was Simon 2-stage design, whereby an initial 38 patients were enrolled and after initial activity was observed with sunitinib malate, a second cohort of patients was enrolled for further study. Sixteen patients remain on treatment.

Of 72 patients who received sunitinib malate, partial responses were achieved in two patients, and stable disease (SD) was achieved in 17 patients (12 with SD for >3 months and 3 for >6 months). Median progression-free survival was 11.1 weeks, with overall survival of 47.7 weeks. The most common treatment-related adverse events (AEs) were nausea and stomatitis, which were generally grade 1/2 in severity. Grade ≥3 non-hematologic treatment-related AEs included fatigue, anorexia, and hand-foot syndrome. Treatment-related grade ≥3 hematologic AEs included reduced platlets, neutrophils, and hemoglobin.

Phase I Studies in Prostate Cancer and Breast Cancer
Also presented at ECCO were results from two Phase I studies in the first-line treatment of both metastatic castrate-resistant prostate cancer, also known as hormone-refractory prostate cancer (HRPC) and advanced breast cancer, showing the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies for both cancers respectively. Preliminary evidence of activity was also observed in both studies.

A phase I, 25-patient dose-finding study found that the combination of sunitinib malate and docetaxel (dcx) + prednisone (pdn) appears to be tolerated with the optimum combination dose (OCD) being sunitinib malate 37.5 mg/day for two weeks, followed by one week off treatment, combined with dcx 75 mg/m2, given intravenously once every three weeks and pdn 5 mg administered twice daily. Docetaxel-based chemotherapy regimens are currently the standard of care for the first-line treatment of patients with HRPC. The most commonly reported treatment-related non-hematologic AEs included fatigue, dysgeusia, nausea, diarrhea and skin discoloration. Grade 3/4 non-hematologic AEs included fatigue, skin discoloration, mucosal inflammation/stomatitis and hand-foot syndrome. Grade 3/4 hematologic abnormalities included anemia, leukopenia, neutropenia and thrombocytopenia. The study is now proceeding to its second phase in which safety and efficacy of this regimen in the first-line treatment of metastatic HRPC will be assessed.

Additionally, preliminary results from a Phase I, 22-patient trial showed the tolerability and safety of sunitinib malate in combination with paclitaxel, a commonly used chemotherapy, in the first-line treatment of advanced breast cancer. No new toxicities emerged other than those seen in previous studies with sunitinib or paclitaxel. A Phase III study of this combination (sunitinib malate + paclitaxel) compared with bevacizumab plus paclitaxel in the first-line treatment of advanced breast cancer is currently underway.

"Some of the most pressing unmet needs in cancer treatment today are in the advanced setting, said Charles Baum, MD PhD, head of oncology development at Pfizer. "We are encouraged by the data presented this week at ECCO, as Pfizer is committed to further exploring the role sunitinib malate may play in the treatment of patients with advanced cancers, both as a single-agent and in combination."

Sunitinib Clinical Research Program
Phase III trials are underway to evaluate the role of sunitinib malate in the treatment of various solid tumors including advanced breast cancer (BC), advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC). The SUN (Studies to UNderstand Sunitinib Malate) Program is a clinical resource for professionals who are interested in learning more about sunitinib malate trials that are open for enrollment. Healthcare professionals can visit The SUN Program Web site at www.suntrials.com.

For more information about sunitinib malate trials currently open and enrolling, please visit www.suntrials.com, www.clinicaltrials.gov.

About SUTENT® (sunitinib malate)
SUTENT is a multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. SUTENT is not approved for the treatment of gastric cancer, hormone-refractory prostate cancer or metastatic breast cancer.

Sunitinib malate works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two important sunitinib malate targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are expressed by many types of solid tumors, and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth. Sunitinib malate also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.

Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on SUTENT.

Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure.

Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. CBCs with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions are fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia and bleeding.

For more information on Sutent and Pfizer Oncology please visit www.pfizer.com.

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Diabetes drug may also offer vascul…

Obesity and Type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease. Obese and diabetic premenopausal women are most at risk...

Read more

AstraZeneca and Lilly receive FDA F…

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016